Ariad Pharm Inc (ARIA) 7.54 $ARIA
ARIAD Announces Distribution Agreements for Iclusig(R) in Latin America and the Middle East/North Africa
BusinessWire - Fri Jun 17, 6:45AM CDT
--~ Agreements Include Buy-Back Provisions in Case of a Change in Control of ARIAD
ARIA: 7.54 (+0.27)
ARIAD (ARIA) Presents Long-Term Phase II Data on Iclusig
Zacks Equity Research - Zacks Investment Research - Tue Jun 14, 5:25PM CDT
ARIAD (ARIA) presented long-term follow-up phase II PACE study data on its leukemia drug, Iclusig.
ARIA: 7.54 (+0.27), BMY: 72.64 (+0.33), ORPN: 1.74 (-0.01), NVS: 80.67 (+0.96)
ARIAD Announces Long-Term Safety and Efficacy Data of Ponatinib from Phase 2 Pace Clinical Trial
BusinessWire - Mon Jun 13, 6:35AM CDT
--~ Overall Survival at Four Years is Estimated to be 77 Percent
ARIA: 7.54 (+0.27)
Shares of ARIA Up 48.8% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Fri Jun 10, 12:15AM CDT
SmarTrend identified an Uptrend for Ariad Pharmaceuticals (NASDAQ:ARIA) on March 1st, 2016 at $5.66. In approximately 3 months, Ariad Pharmaceuticals has returned 48.76% as of today's recent price of $8.42.
ARIA: 7.54 (+0.27)
ARIAD to Host Analyst & Investor Day in New York City
BusinessWire - Wed Jun 08, 6:35AM CDT
ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that it will host an Analyst & Investor Day for its research analysts and institutional investors on Friday, June 17 at 8:30 a.m. (EDT) in New York City. Paris Panayiotopoulos, president and chief executive officer of ARIAD, will host the event along with other key members of ARIAD senior management. The meeting will focus on ARIAD's completion of its corporate strategic review, as well as provide an update on continued progress in its research and development and commercial programs. Expert medical leaders in the fields of chronic myeloid leukemia and non-small cell lung cancer will be featured speakers and discussants at the meeting.
ARIA: 7.54 (+0.27)
ARIAD (ARIA) Presents Phase II Study Data on Cancer Drug
Zacks Equity Research - Zacks Investment Research - Tue Jun 07, 11:00AM CDT
ARIAD (ARIA) presented updated phase II ALTA study data on brigatinib for the treatment of refractory ALK+ non-small cell lung cancer patients.
ATNM: 1.75 (-0.02), PFE: 34.59 (+0.12), JNP: 7.08 (+0.10), ARIA: 7.54 (+0.27)
Ariad Pharmaceuticals Set to Possibly Rebound After Yesterday's Selloff of 1.22%
Comtex SmarTrend(R) - Mon Jun 06, 4:17PM CDT
Ariad Pharmaceuticals (NASDAQ:ARIA) traded in a range yesterday that spanned from a low of $8.58 to a high of $9.12. Yesterday, the shares fell 1.2%, which took the trading range below the 3-day low of $8.63 on volume of 5.4 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
ARIA: 7.54 (+0.27)
Covered Call Alerts For Canadian Solar, BP, Lumber Liquidators, Ariad Pharmaceuticals and Walmart Stores Inc. Released By InvestorsObserver
PR Newswire - Mon Jun 06, 9:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for CSIQ, BP, LL, ARIA and WMT.
WMT: 72.10 (+0.35), BP: 34.63 (+0.74), LL: 15.78 (+0.36), ARIA: 7.54 (+0.27), CSIQ: 16.25 (+0.42)
ARIAD's Investigational Medicine Brigatinib Demonstrates 54 Percent Confirmed Objective Response Rate and 12.9-Month Median Progression-Free Survival in ALTA Study
BusinessWire - Mon Jun 06, 6:35AM CDT
--~ Data from Pivotal Study in Refractory ALK Positive Non-Small Cell Lung Cancer Patients
ARIA: 7.54 (+0.27)
ARIAD Presents Data from Mutational Profiling in Crizotinib-Resistant Patients Treated with Investigational Medicine Brigatinib Showing Similar Response Rates in Patients with and without Secondary ALK Mutations
BusinessWire - Sat Jun 04, 6:35AM CDT
ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced clinical data from an analysis aimed at characterizing the activity of its investigational tyrosine kinase inhibitor (TKI), brigatinib, in patients with anaplastic lymphoma kinase positive (ALK+) advanced non-small cell lung cancer (NSCLC) who have progressed on crizotinib. The analysis was based on ALK mutation status as determined by next-generation sequencing (NGS) of tumor tissue collected from the ongoing Phase 1/2 and ALTA clinical trials.
ARIA: 7.54 (+0.27)
ARIAD Presents Long-Term Phase 1/2 Trial Follow up on Investigational Drug Brigatinib with Median Time on Treatment of 17 Months in ALK+ NSCLC Patients
BusinessWire - Sat Jun 04, 6:35AM CDT
--~ Data from Phase 1/2 Clinical Trial Presented at 2016 ASCO Meeting
ARIA: 7.54 (+0.27)
Uptrend Call Working As Ariad Pharmaceuticals Stock Rises 56.0% (ARIA)
Comtex SmarTrend(R) - Thu Jun 02, 12:41PM CDT
SmarTrend identified an Uptrend for Ariad Pharmaceuticals (NASDAQ:ARIA) on March 1st, 2016 at $5.66. In approximately 3 months, Ariad Pharmaceuticals has returned 56.01% as of today's recent price of $8.83.
ARIA: 7.54 (+0.27)
ARIAD Completes the Sale of Its European Operations and Out-License of European Rights to Iclusig(R)
BusinessWire - Thu Jun 02, 6:35AM CDT
--~ ARIAD Receives $140 Million Upfront Payment, $135 million to be Received in Potential Oncology Milestones, Tiered Royalty Payments of Between 32% and 50%
INCY: 81.66 (+3.16), ARIA: 7.54 (+0.27)
ARIAD (ARIA) Commences Phase I/II Study on Cancer Drug
Zacks Equity Research - Zacks Investment Research - Wed Jun 01, 4:05PM CDT
ARIAD (ARIA) announced the initiation of a phase I/IIstudy on AP32788 for the treatment of non-small cell lung cancer with specific mutations in EGFR or HER2.
APRI: 0.47 (-0.01), JNP: 7.08 (+0.10), ARIA: 7.54 (+0.27)
Ariad Pharmaceuticals (ARIA) Jumps: Stock Moves Up 7.8%
Zacks Equity Research - Zacks Investment Research - Wed Jun 01, 7:25AM CDT
Ariad Pharmaceuticals Inc. (ARIA) moved big last session, shares jump almost 8% on the day.
JNP: 7.08 (+0.10), ARIA: 7.54 (+0.27)
ARIAD to Present at the Jefferies 2016 Global Healthcare Conference
BusinessWire - Wed Jun 01, 6:35AM CDT
ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that it will present at the Jefferies 2016 Global Healthcare Conference being held in New York City. Paris Panayiotopoulos, president and chief executive officer, will provide an overview of the Company's business on Wednesday, June 8, 2016 at 11:00 a.m. (ET).
ARIA: 7.54 (+0.27)
Ariad Pharmaceuticals Rises 7.92% on Heavy Volume: Watch For Potential Pullback
Comtex SmarTrend(R) - Tue May 31, 3:07PM CDT
Ariad Pharmaceuticals (NASDAQ:ARIA) traded in a range yesterday that spanned from a low of $8.32 to a high of $8.96. Yesterday, the shares gained 7.9%, which took the trading range above the 3-day high of $8.22 on volume of 5.7 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
ARIA: 7.54 (+0.27)
Surging Earnings Estimates Signal Good News for Ariad Pharmaceuticals (ARIA)
Zacks Equity Research - Zacks Investment Research - Tue May 31, 7:57AM CDT
Ariad Pharmaceuticals (ARIA) could be good choice for investors as it is seeing decent short-term momentum and positive earnings estimate revisions.
ARIA: 7.54 (+0.27)
ARIAD Announces Initiation of Phase 1/2 Clinical Trial of AP32788, an Investigational Oral Inhibitor of EGFR and HER2, in Patients with Non-Small Cell Lung Cancer
BusinessWire - Tue May 31, 6:35AM CDT
ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced initiation of the Phase 1/2 clinical trial of AP32788, an investigational tyrosine kinase inhibitor (TKI) designed as a targeted therapy for patients with non-small cell lung cancer (NSCLC) with specific mutations in EGFR or HER2. AP32788 targets tumors driven by EGFR or HER2 kinases and was designed to achieve selective inhibition of these kinases with exon 20 mutations. There are currently no approved targeted treatment options available for the approximately four to nine percent of EGFR-mutated lung tumors with exon 20 insertion mutations in NSCLC patients.(1) Additionally, approximately two percent of NSCLC patients(2) have HER2 mutations, with the majority having exon 20 insertion mutations.
ARIA: 7.54 (+0.27)
Ariad Pharmaceuticals Up 44.0% Since SmarTrend Uptrend Call (ARIA)
Comtex SmarTrend(R) - Thu May 26, 12:15AM CDT
SmarTrend identified an Uptrend for Ariad Pharmaceuticals (NASDAQ:ARIA) on March 1st, 2016 at $5.66. In approximately 3 months, Ariad Pharmaceuticals has returned 43.99% as of today's recent price of $8.15.
ARIA: 7.54 (+0.27)
ARIAD Announces Distribution Agreements for Iclusig(R) in Latin America and the Middle East/North Africa
BusinessWire - Fri Jun 17, 6:45AM CDT
--~ Agreements Include Buy-Back Provisions in Case of a Change in Control of ARIAD
ARIA: 7.54 (+0.27)
ARIAD (ARIA) Presents Long-Term Phase II Data on Iclusig
Zacks Equity Research - Zacks Investment Research - Tue Jun 14, 5:25PM CDT
ARIAD (ARIA) presented long-term follow-up phase II PACE study data on its leukemia drug, Iclusig.
ARIA: 7.54 (+0.27), BMY: 72.64 (+0.33), ORPN: 1.74 (-0.01), NVS: 80.67 (+0.96)
ARIAD Announces Long-Term Safety and Efficacy Data of Ponatinib from Phase 2 Pace Clinical Trial
BusinessWire - Mon Jun 13, 6:35AM CDT
--~ Overall Survival at Four Years is Estimated to be 77 Percent
ARIA: 7.54 (+0.27)
Shares of ARIA Up 48.8% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Fri Jun 10, 12:15AM CDT
SmarTrend identified an Uptrend for Ariad Pharmaceuticals (NASDAQ:ARIA) on March 1st, 2016 at $5.66. In approximately 3 months, Ariad Pharmaceuticals has returned 48.76% as of today's recent price of $8.42.
ARIA: 7.54 (+0.27)
ARIAD to Host Analyst & Investor Day in New York City
BusinessWire - Wed Jun 08, 6:35AM CDT
ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that it will host an Analyst & Investor Day for its research analysts and institutional investors on Friday, June 17 at 8:30 a.m. (EDT) in New York City. Paris Panayiotopoulos, president and chief executive officer of ARIAD, will host the event along with other key members of ARIAD senior management. The meeting will focus on ARIAD's completion of its corporate strategic review, as well as provide an update on continued progress in its research and development and commercial programs. Expert medical leaders in the fields of chronic myeloid leukemia and non-small cell lung cancer will be featured speakers and discussants at the meeting.
ARIA: 7.54 (+0.27)
ARIAD (ARIA) Presents Phase II Study Data on Cancer Drug
Zacks Equity Research - Zacks Investment Research - Tue Jun 07, 11:00AM CDT
ARIAD (ARIA) presented updated phase II ALTA study data on brigatinib for the treatment of refractory ALK+ non-small cell lung cancer patients.
ATNM: 1.75 (-0.02), PFE: 34.59 (+0.12), JNP: 7.08 (+0.10), ARIA: 7.54 (+0.27)
Ariad Pharmaceuticals Set to Possibly Rebound After Yesterday's Selloff of 1.22%
Comtex SmarTrend(R) - Mon Jun 06, 4:17PM CDT
Ariad Pharmaceuticals (NASDAQ:ARIA) traded in a range yesterday that spanned from a low of $8.58 to a high of $9.12. Yesterday, the shares fell 1.2%, which took the trading range below the 3-day low of $8.63 on volume of 5.4 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
ARIA: 7.54 (+0.27)
Covered Call Alerts For Canadian Solar, BP, Lumber Liquidators, Ariad Pharmaceuticals and Walmart Stores Inc. Released By InvestorsObserver
PR Newswire - Mon Jun 06, 9:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for CSIQ, BP, LL, ARIA and WMT.
WMT: 72.10 (+0.35), BP: 34.63 (+0.74), LL: 15.78 (+0.36), ARIA: 7.54 (+0.27), CSIQ: 16.25 (+0.42)
ARIAD's Investigational Medicine Brigatinib Demonstrates 54 Percent Confirmed Objective Response Rate and 12.9-Month Median Progression-Free Survival in ALTA Study
BusinessWire - Mon Jun 06, 6:35AM CDT
--~ Data from Pivotal Study in Refractory ALK Positive Non-Small Cell Lung Cancer Patients
ARIA: 7.54 (+0.27)
ARIAD Presents Data from Mutational Profiling in Crizotinib-Resistant Patients Treated with Investigational Medicine Brigatinib Showing Similar Response Rates in Patients with and without Secondary ALK Mutations
BusinessWire - Sat Jun 04, 6:35AM CDT
ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced clinical data from an analysis aimed at characterizing the activity of its investigational tyrosine kinase inhibitor (TKI), brigatinib, in patients with anaplastic lymphoma kinase positive (ALK+) advanced non-small cell lung cancer (NSCLC) who have progressed on crizotinib. The analysis was based on ALK mutation status as determined by next-generation sequencing (NGS) of tumor tissue collected from the ongoing Phase 1/2 and ALTA clinical trials.
ARIA: 7.54 (+0.27)
ARIAD Presents Long-Term Phase 1/2 Trial Follow up on Investigational Drug Brigatinib with Median Time on Treatment of 17 Months in ALK+ NSCLC Patients
BusinessWire - Sat Jun 04, 6:35AM CDT
--~ Data from Phase 1/2 Clinical Trial Presented at 2016 ASCO Meeting
ARIA: 7.54 (+0.27)
Uptrend Call Working As Ariad Pharmaceuticals Stock Rises 56.0% (ARIA)
Comtex SmarTrend(R) - Thu Jun 02, 12:41PM CDT
SmarTrend identified an Uptrend for Ariad Pharmaceuticals (NASDAQ:ARIA) on March 1st, 2016 at $5.66. In approximately 3 months, Ariad Pharmaceuticals has returned 56.01% as of today's recent price of $8.83.
ARIA: 7.54 (+0.27)
ARIAD Completes the Sale of Its European Operations and Out-License of European Rights to Iclusig(R)
BusinessWire - Thu Jun 02, 6:35AM CDT
--~ ARIAD Receives $140 Million Upfront Payment, $135 million to be Received in Potential Oncology Milestones, Tiered Royalty Payments of Between 32% and 50%
INCY: 81.66 (+3.16), ARIA: 7.54 (+0.27)
ARIAD (ARIA) Commences Phase I/II Study on Cancer Drug
Zacks Equity Research - Zacks Investment Research - Wed Jun 01, 4:05PM CDT
ARIAD (ARIA) announced the initiation of a phase I/IIstudy on AP32788 for the treatment of non-small cell lung cancer with specific mutations in EGFR or HER2.
APRI: 0.47 (-0.01), JNP: 7.08 (+0.10), ARIA: 7.54 (+0.27)
Ariad Pharmaceuticals (ARIA) Jumps: Stock Moves Up 7.8%
Zacks Equity Research - Zacks Investment Research - Wed Jun 01, 7:25AM CDT
Ariad Pharmaceuticals Inc. (ARIA) moved big last session, shares jump almost 8% on the day.
JNP: 7.08 (+0.10), ARIA: 7.54 (+0.27)
ARIAD to Present at the Jefferies 2016 Global Healthcare Conference
BusinessWire - Wed Jun 01, 6:35AM CDT
ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that it will present at the Jefferies 2016 Global Healthcare Conference being held in New York City. Paris Panayiotopoulos, president and chief executive officer, will provide an overview of the Company's business on Wednesday, June 8, 2016 at 11:00 a.m. (ET).
ARIA: 7.54 (+0.27)
Ariad Pharmaceuticals Rises 7.92% on Heavy Volume: Watch For Potential Pullback
Comtex SmarTrend(R) - Tue May 31, 3:07PM CDT
Ariad Pharmaceuticals (NASDAQ:ARIA) traded in a range yesterday that spanned from a low of $8.32 to a high of $8.96. Yesterday, the shares gained 7.9%, which took the trading range above the 3-day high of $8.22 on volume of 5.7 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
ARIA: 7.54 (+0.27)
Surging Earnings Estimates Signal Good News for Ariad Pharmaceuticals (ARIA)
Zacks Equity Research - Zacks Investment Research - Tue May 31, 7:57AM CDT
Ariad Pharmaceuticals (ARIA) could be good choice for investors as it is seeing decent short-term momentum and positive earnings estimate revisions.
ARIA: 7.54 (+0.27)
ARIAD Announces Initiation of Phase 1/2 Clinical Trial of AP32788, an Investigational Oral Inhibitor of EGFR and HER2, in Patients with Non-Small Cell Lung Cancer
BusinessWire - Tue May 31, 6:35AM CDT
ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced initiation of the Phase 1/2 clinical trial of AP32788, an investigational tyrosine kinase inhibitor (TKI) designed as a targeted therapy for patients with non-small cell lung cancer (NSCLC) with specific mutations in EGFR or HER2. AP32788 targets tumors driven by EGFR or HER2 kinases and was designed to achieve selective inhibition of these kinases with exon 20 mutations. There are currently no approved targeted treatment options available for the approximately four to nine percent of EGFR-mutated lung tumors with exon 20 insertion mutations in NSCLC patients.(1) Additionally, approximately two percent of NSCLC patients(2) have HER2 mutations, with the majority having exon 20 insertion mutations.
ARIA: 7.54 (+0.27)
Ariad Pharmaceuticals Up 44.0% Since SmarTrend Uptrend Call (ARIA)
Comtex SmarTrend(R) - Thu May 26, 12:15AM CDT
SmarTrend identified an Uptrend for Ariad Pharmaceuticals (NASDAQ:ARIA) on March 1st, 2016 at $5.66. In approximately 3 months, Ariad Pharmaceuticals has returned 43.99% as of today's recent price of $8.15.
ARIA: 7.54 (+0.27)
